Kriya Therapeutics Inc., with dual headquarters in Durham and Palo Alto, Calif., has acquired a gene therapy startup that Kriya says will align with its approach to treating metabolic disease.
Read More
Durham biotech Kriya Therapeutics which says it represents “gene therapy redefined,” has raised $150 million for its gene therapy programs.
Read More
Kriya Therapeutics, which is based in RTP and has brought in more than $330 million in funding, has bought yet another gene therapy startup for its portfolio.
Read More
Kriya Therapeutics, Inc., a gene therapy company with locations in California and RTP, has raised $270 million more in capital.
Read More
Entrepreneurial companies continue to make headlines as 2022 gets off to a fast business start. Here is the latest news.
Read More
The acquisition comes after Kriya landed a whopping $100 million in capital in 2021. That’s on top of $80.5 million raised in 2020.
Read More
Kriya Therapeutics is launching a new division focused on developing gene therapies for rare and prevalent ocular diseases. Here are the details.
Read More
Kriya Therapeutics is poised to revolutionize gene therapies for highly serious diseases like diabetes and severe obesity after landing a whopping $100 million in capital.
Read More
Kriya Therapeutics, which has operations in the Triangle and Silicon Valley, is even more flush with cash than a year ago, adding a second round of financing totalling $100 million.
Read More
